TRBUŠEK, Martin, Jana ŠMARDOVÁ, Jitka MALČÍKOVÁ, Ludmila ŠEBEJOVÁ, Petr DOBEŠ, Miluše SVITÁKOVÁ, Vladimíra VRANOVÁ, Marek MRÁZ, Hana SKUHROVÁ FRANCOVÁ, Michael DOUBEK, Yvona BRYCHTOVÁ, Petr KUGLÍK, Šárka POSPÍŠILOVÁ and Jiří MAYER. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in Chronic lymphocytic leukemia. Journal of Clinical Oncology. USA: American Society of Clinical Oncology, 2011, vol. 29, No 19, p. 2703-2708. ISSN 0732-183X. Available from: https://dx.doi.org/10.1200/JCO.2011.34.7872.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in Chronic lymphocytic leukemia
Name in Czech Missence mutace lokalizovane ve strukturnich DNAvazebnych motivech p53 jsou asociovany s extremne spatnym prezitim u chronicke lymfocytarni leukemie
Authors TRBUŠEK, Martin (203 Czech Republic, guarantor, belonging to the institution), Jana ŠMARDOVÁ (203 Czech Republic, belonging to the institution), Jitka MALČÍKOVÁ (203 Czech Republic, belonging to the institution), Ludmila ŠEBEJOVÁ (203 Czech Republic, belonging to the institution), Petr DOBEŠ (203 Czech Republic, belonging to the institution), Miluše SVITÁKOVÁ (203 Czech Republic, belonging to the institution), Vladimíra VRANOVÁ (703 Slovakia, belonging to the institution), Marek MRÁZ (203 Czech Republic, belonging to the institution), Hana SKUHROVÁ FRANCOVÁ (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Petr KUGLÍK (203 Czech Republic, belonging to the institution), Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution).
Edition Journal of Clinical Oncology, USA, American Society of Clinical Oncology, 2011, 0732-183X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 18.372
RIV identification code RIV/00216224:14740/11:00052704
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1200/JCO.2011.34.7872
UT WoS 000292210500024
Keywords in English CLL; TP53; DNA-binding motifs; survival
Tags ok, rivok
Tags International impact
Changed by Changed by: Olga Křížová, učo 56639. Changed: 7/4/2012 06:28.
Abstract
Purpose There is a distinct connection between TP53 defects and poor prognosis in chronic lymphocytic leukemia (CLL). It remains unclear whether patients harboring TP53 mutations represent a homogenous prognostic group. Patients and Methods We evaluated the survival of patients with CLL and p53 defects identified at our institution by p53 yeast functional assay and complementary interphase fluorescence in situ hybridization analysis detecting del(17p) from 2003 to 2010. Results A defect of the TP53 gene was identified in 100 of 550 patients. p53 mutations were strongly associated with the deletion of 17p and the unmutated IgVH locus (both P .001). Survival assessed from the time of abnormality detection was significantly reduced in patients with both missense (P .001) and nonmissense p53 mutations (P .004). In addition, patients harboring missense mutation located in p53 DNA-binding motifs (DBMs), structurally well-defined parts of the DNA-binding domain, manifested a clearly shorter median survival (12 months) compared with patients having missense mutations outside DBMs (41 months; P .002) or nonmissense alterations (36 months; P .005). The difference in survival was similar in the analysis limited to patients harboring mutation accompanied by del(17p) and was also confirmed in a subgroup harboring TP53 defect at diagnosis. The patients with p53 DBMs mutation (at diagnosis) also manifested a short median time to first therapy (TTFT; 1 month). Conclusion The substantially worse survival and the short TTFT suggest a strong mutated p53 gain-of-function phenotype in patients with CLL with DBMs mutations. The impact of p53 DBMs mutations on prognosis and response to therapy should be analyzed in investigative clinical trials.
Abstract (in Czech)
Existuje prime spojeni mezi defekty v genu TP53 a spatnou prognozou u chronicke lymfocytarni leukemie. Zustava ale nejasne, zda pacienti, kteri maji mutace v genu TP53 reprezentuji homogenni prognostickou skupinu. Hodnotili jsme preziti pacientu s CLL a defekty v p53 identifikovanych v nasi laboratori pomoci kvasinkove funkcni analyzy p53 a komplementarne interfazni fluorescencni in situ hybridizacni analyzou detekujici del(17p) od roku 2003 do roku 2010. Defekty v genu TP53 byly identifikovany ve 100 z 550 pacientu. Mutace v p53 byly silne asociovany s deleci 17p a nemutovanym lokusem IgVH (oba P .001). Preziti pacientu stanovene od data detekce abnormality bylo signifikantne snizene u pacientu s missence (P .001) i non-missence p53 mutacemi (P= .004).
Links
MSM0021622430, plan (intention)Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie
Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies
NS10448, research and development projectName: Podrobná analýza teplotně závislých mutantů nádorového supresoru p53 v lidských buňkách
Investor: Ministry of Health of the CR
PrintDisplayed: 4/8/2024 22:21